Skip to Content
Merck

SLX4IP Antagonizes Promiscuous BLM Activity during ALT Maintenance.

Molecular cell (2019-08-27)
Stephanie Panier, Marija Maric, Graeme Hewitt, Emily Mason-Osann, Himabindu Gali, Anqi Dai, Adam Labadorf, Jean-Hugues Guervilly, Philip Ruis, Sandra Segura-Bayona, Ondrej Belan, Paulina Marzec, Pierre-Henri L Gaillard, Rachel L Flynn, Simon J Boulton
ABSTRACT

Cancer cells acquire unlimited proliferative capacity by either re-expressing telomerase or inducing alternative lengthening of telomeres (ALT), which relies on telomere recombination. Here, we show that ALT recombination requires coordinate regulation of the SMX and BTR complexes to ensure the appropriate balance of resolution and dissolution activities at recombining telomeres. Critical to this control is SLX4IP, which accumulates at ALT telomeres and interacts with SLX4, XPF, and BLM. Loss of SLX4IP increases ALT-related phenotypes, which is incompatible with cell growth following concomitant loss of SLX4. Inactivation of BLM is sufficient to rescue telomere aggregation and the synthetic growth defect in this context, suggesting that SLX4IP favors SMX-dependent resolution by antagonizing promiscuous BLM activity during ALT recombination. Finally, we show that SLX4IP is inactivated in a subset of ALT-positive osteosarcomas. Collectively, our findings uncover an SLX4IP-dependent regulatory mechanism critical for telomere maintenance in ALT cancer cells.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(S)-(+)-Camptothecin, ≥90% (HPLC), powder
Sigma-Aldrich
Cycloheximide solution, Ready-Made Solution, microbial, 100 mg/mL in DMSO, Suitable for cell culture
Sigma-Aldrich
5-Bromo-2′-deoxyuridine, ≥99% (HPLC)
Sigma-Aldrich
Nocodazole, ≥99% (TLC), powder
Sigma-Aldrich
Doxycycline hydrochloride